GSIE - ETF AI Analysis
Top Page
Goldman Sachs ActiveBeta International Equity ETF (GSIE)
GSIE, the Goldman Sachs ActiveBeta International Equity ETF, has a solid overall rating driven mainly by strong, diversified holdings in global leaders like ASML, Novartis, HSBC, and AstraZeneca, which show robust financial performance, healthy balance sheets, and positive earnings outlooks. Some positions, such as Recruit Holdings and Shell, introduce risks around potential overvaluation, mixed momentum, and revenue or cash flow challenges, which slightly weigh on the fund’s rating. The main risk factor is exposure to individual stocks with high valuations or overbought signals, which could lead to short-term volatility even though the overall portfolio quality remains strong.
GSIE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 5.93B
- Region
- Developed Markets
- Expense Ratio
- 0.25%
- Beta
- 0.69
- Issuer
- Goldman Sachs
- Inception Date
- Nov 06, 2015
- Dividend Yield
- 2.63%
- Asset Class
- Equity
- Index Tracked
- Stuttgart Goldman Sachs ActiveBeta Intl.Equity (USD)
GSIE Summary
GSIE is the Goldman Sachs ActiveBeta International Equity ETF, which follows the Stuttgart Goldman Sachs ActiveBeta International Equity index and invests in stocks from many countries outside the U.S., like Japan, the UK, and Canada. It holds a wide mix of sectors, including financials, industrials, and technology, with well-known companies such as ASML Holding and Royal Bank of Canada. Investors might consider GSIE to diversify beyond the U.S. market and seek long-term growth from global companies. A key risk is that international stock prices can go up and down with global markets and currency changes.
How much will it cost me?
This ETF has an expense ratio of 0.25%, which means you’ll pay about $2.50 per year for every $1,000 invested. That’s slightly higher than the cheapest passive index ETFs because GSIE uses an “ActiveBeta” factor strategy rather than simple market-cap indexing, but it’s still reasonably low-cost overall.
What would affect this ETF?
GSIE could benefit if developed markets outside the U.S. grow steadily, especially in financials, industrials, and technology, and if global demand for healthcare and energy supports companies like Roche, Novartis, ASML, and Shell. On the negative side, slower economic growth abroad, banking or energy sector stress, or unfavorable regulations in key regions like Europe, Canada, and Japan could weigh on the ETF’s performance.
GSIE Top 10 Holdings
GSIE leans heavily into non-U.S. blue chips, with semiconductor tester Advantest and chip-equipment giant ASML acting as key engines of recent gains, riding strong momentum in global tech. On the defensive side, AstraZeneca has been lagging, taking a bit of shine off the fund’s otherwise solid health care exposure, while HSBC’s weaker stretch has kept the financials from fully pulling their weight. Still, steady performance from Royal Bank of Canada and Toronto-Dominion, plus rising names like Roche and Novartis, gives GSIE a diversified, developed-markets ex-U.S. backbone.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 1.99% | $119.30M | EUR 510.94B | 37.88% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 CH:NOVN | Novartis AG | 1.08% | $64.60M | CHF 245.77B | 32.03% | 80Outperform |
 JP:6857 | Advantest | 0.96% | $57.72M | JPY 24.12T | 43.93% | 75Outperform |
 GB:HSBA | HSBC Holdings | 1.01% | $60.63M | GBP 225.86B | 20.41% | 80Outperform |
 TSE:TD | Toronto Dominion Bank | 0.87% | $52.08M | CAD 302.30B | 51.56% | 74Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 JP:6098 | Recruit Holdings Co | 0.78% | $46.99M | JPY 24.33T | 149.41% | 67Neutral |
 GB:SHEL | Shell (UK) | 0.76% | $45.60M | GBP 215.38B | 32.15% | 73Outperform |
GSIE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSIE, the sentiment is Positive. The current price of 45.98 is below the 20-day moving average (MA) of 46.10, below the 50-day MA of 46.55, and above the 200-day MA of 45.26, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 62.40 is Neutral, neither overbought nor oversold. The STOCH value of 70.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSIE.
GSIE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GSIE | $45.98 | $51.00(10.92% Upside) | $5.93B | 0.25% | 65Neutral |
 LVHI | $43.09 | $47.73(10.77% Upside) | $6.39B | 0.40% | 67Neutral |
 IMTM | $48.75 | $67.12(37.68% Upside) | $4.14B | 0.30% | 69Neutral |
 IDMO | $55.54 | $74.64(34.38% Upside) | $4.12B | 0.25% | 71Outperform |
 INTF | $40.84 | $50.89(24.60% Upside) | $3.69B | 0.16% | 64Neutral |
 PXF | $75.52 | $94.05(24.53% Upside) | $2.99B | 0.43% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GSIE | Goldman Sachs ActiveBeta International Equity ETF | 45.98 | 5.81 | 14.46% | |
| LVHI | Legg Mason International Low Volatility High Dividend ETF | 43.09 | 8.87 | 25.91% | |
| IMTM | iShares MSCI Intl Momentum Factor ETF | 48.75 | 3.10 | 6.79% | |
| IDMO | Invesco S&P International Developed Momentum ETF | 55.54 | 3.79 | 7.33% | |
| INTF | iShares MSCI Intl Multifactor ETF | 40.84 | 5.63 | 15.98% | |
| PXF | Invesco FTSE RAFI Developed Markets ex-U.S. ETF | 75.52 | 15.27 | 25.35% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.